Piper Jaffray Maintains Overweight Rating On Salix Pharmaceuticals, Ltd. (SLXP)

Analysts David Amesellem and Michael Dinerman at Piper Jaffray have maintained their Overweight rating on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP).

Analysts say that prescription (Rx) data since the late March FDA approval shows a clear acceleration in Rx growth. Analysts believe that the strong Rx trends indicate solid demand and improved reimbursement in HE.

According to analysts, Salix Pharmaceuticals is on the cusp of dramatic earnings growth with the growth in HE adoption and their expansion into irritable bowel syndrome in 2011. The price target for the company has been maintained at $58.